[1] Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology, 2003, 124(1): 91-96.
[2] Angeli P, Gines P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut, 2015, 64(4): 531-537.
[3] Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract, 2012, 120(4): c179-184.
[4] Angeli P, Garcia-Tsao G, Nadim M, et al. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J Hepatol, 2019, 71(4): 811-822.
[5] Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut, 2022, 71(1): 156-162.
[6] Sanyal A, Van Natta M, Clark J, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med, 2021, 385(17): 1559-1569.
[7] Targher G, Byrne C. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. Nat Rev Nephrol, 2017, 13(5): 297-310.
[8] Shiha G, Korenjak M, Eskridge W, et al. Redefining fatty liver disease: an international patient perspective. Lancet Gastroenterol Hepatol, 2021, 6(1): 73-79.
[9] Di Sessa A, Guarino S, Melone R, et al. Relationship between nonalcoholic fatty liver disease and chronic kidney disease could start in childhood. World J Gastroenterol, 2021, 27(34): 5793-5795.
[10] Choe A, Ryu D, Kim H, et al. Noninvasive indices for predicting nonalcoholic fatty liver disease in patients with chronic kidney disease. BMC Nephrol, 2020, 21(1): 50.
[11] Heda R, Yazawa M, Shi M, et al. Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect. World J Gastroenterol, 2021, 27(17): 1864-1882.
[12] Shah A, Amarapurkar D. Spectrum of hepatitis B and renal involvement. Liver Int, 2018, 38(1): 23-32.
[13] Kayode-Ajala F, Ejikeme C, Picone J, et al. A case of hepatitis C related mixed cryoglobulinemia syndrome. J Community Hosp Intern Med Perspect, 2022, 12(2): 53-56.
[14] Luciano R, Castano E, Moeckel G, et al. Bile acid nephropathy in a bodybuilder abusing an anabolic androgenic steroid. Am J Kidney Dis, 2014, 64(3): 473-476.
[15] Priyaa V, Srinivas B, Gochhait D, et al. Cholemic nephrosis: An autopsy study of a forgotten entity. Turk patoloji dergisi, 2021, 37(3): 212-218.
[16] Heidari R, Mandegani L, Ghanbarinejad V, et al. Mitochondrial dysfunction as a mechanism involved in the pathogenesis of cirrhosis-associated cholemic nephropathy. Biomed Pharmacother, 2019, 109: 271-280.
[17] Kaler B, Karram T, Morgan W, et al. Are bile acids involved in the renal dysfunction of obstructive jaundice? An experimental study in bile duct ligated rats. Ren Fail, 2004, 26(5): 507-516.
[18] Adiyanti S, Loho T. Acute kidney injury (AKI) biomarker. Acta Med Indones, 2012, 44(3): 246-255.
[19] Washburn K, Zappitelli M, Arikan A, et al. Urinary interleukin-18 is an acute kidney injury biomarker in critically ill children. Nephrol Dial Transplant, 2008, 23(2): 566-572.
[20] Vaidya V, Ozer J, Dieterle F, et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol, 2010, 28(5): 478-485.
[21] Portilla D, Dent C, Sugaya T, et al. Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int, 2008, 73(4): 465-472.
[22] Parikh C, Mansour S. Perspective on clinical application of biomarkers in AKI. J Am Soc Nephrol, 2017, 28(6): 1677-1685.
[23] Biggins S, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology (Baltimore, Md), 2021, 74(2): 1014-1048.
[24] Ala M. SGLT2 inhibition for cardiovascular diseases, chronic kidney disease, and NAFLD. Endocrinology, 2021, 162(12):1231-1237.
[25] Fickert P, Rosenkranz A. Cholemic nephropathy reloaded. Semin Liver Dis, 2020, 40(1): 91-100.
[26] Krones E, Eller K, Pollheimer M, et al. Norursodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice. J Hepatol, 2017, 67(1): 110-119. |
